Choose language
< Return to main menu
Peptide synthesis_Facilities Peptide manufacturing_Facilities

Facilities

About Us

About Us

Services & Solutions

News

Resource

Contact

Career

Facilities

Facilities

Quality

EHS

IP

Peptide synthesis company_Shanghai

Shanghai, China

Peptide discovery, formulation development and manufacturing

Shanghai site is WuXi STA's headquarter, including chemistry, biology, and clinical service, providing one-stop service include chemistry, biology, testing, and formulation service for your peptide projects.

The peptide drug discovery synthesis team in Shanghai was established in 2009, covering all types of peptide related services including synthesis-purification-analysis of peptide / peptide-small molecule conjugate / peptide-drug conjugate products, with both FFS and FTE resources.

We have a dedicated formulation development team for oral and injectable peptide drug development and manufacturing with on site analytical and QA support.

Address:

288 Fute Zhong Road Waigaoqiao Free Trade

Zone Shanghai 200131, China

GMP peptide manufacturing_Wuhan

Wuhan, China

Peptide discovery and research services

Wuhan site has started operation since 2012 and provides state-of-the-art peptide drug discovery and research services with FTE and FFS resourses.

Our team is highly experienced with peptide and peptide-small molecule conjugate synthesis, serving 100+ customers worldwide with 10,000+ products every year.  In addition, we are capable to support peptide non-GMP production up to kg scale.

666 Gaoxin Road East Lake High-tech Development Zone

Wuhan, 430075, China

Custom peptide synthesis_Changzhou

Changzhou, China

Peptide API process R&D and manufacturing

Changzhou site is a 74 acre fully integrated R&D and cGMP manufacturing campus providing a unique one-site solution for APIs and advanced intermediates, including small molecule, HPAPI, oligonucleotide, peptide and complex chemical conjugate, through preclinical and clinical development to global commercial launch.  

Currently with several hundreds of scientists dedicated to peptide CMC, the site has built strong chemistry capability of process R&D for synthesis of peptide, ligand and linker as well as various of peptide-based conjugates.

The site has also built peptide manufacturing capacity that includes 12 lines with reactors up to 1,000 L for solid phase peptide synthesis.  

Changzhou site offers peptide API process R&D, manufacturing, analytical and quality control.

Address:

589 North Yulong Road XinBei District, Changzhou, 213127, China

xinjiapojidi.jpg

Singapore

Peptide API processs development & manufacturing

WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced a plan to build a new 50-acre R&D and manufacturing site in Singapore on July 19, 2022, totally 7 plants in plan. The company intends to invest up to S$2 billion (approximately US$1.43 billion) to construct and operationalize the site, which aims to further enable global partners to advance healthcare innovations. The investment is expected to be made in stages over the next 10 years, depending on the company's business needs.


In Phase I project, we plan to build 2 plants for small molecule API with 350+ m3 TRV and 1 plant for oligonucleotides, peptides and complex chemical conjugates. It's expected to start operation in 2026. 


Peptide synthesis company_Taixing

Taixing, China

Peptide and conjugate API Manufacturing

With a total area of 170 acres, the Taixing site is designed to support global partners with integrated API process R&D and manufacturing from preclinical to commercial stages. The first phase of the project, with an area of about 53 acres, is expected to be fully operational in 2025, with an annual capacity of more than 100 metric tons of drug substance.

The first phase of the project also includes industry-leading new molecular modality platforms from laboratory to commercial scale, such as high potency APIs, oligonucleotides and peptides.


Address:

Taixing Economic Development Zone, Jiangsu China

Peptide manufacturing_WuXi city

Wuxi city, China

Peptide formulation development and manufacturing

The Wuxi city site is an integrated drug product R&D and manufacturing campus, including one R&D center and two oral solid commercial-scale plants. The R&D center with an area of 2.8 acres to house several hundreds of scientists, includes oral dosage platform, sterile injectable platform as well as analytical testing platform. The two oral solid commercial-scale plants provide manufacturing, packaging, and labeling services. The newly opened R&D center includes oral, injectable and analytical platforms.

The parenteral formulation platform at our Wuxi city site is designed for vials, cartridge and pre-filled syringes with state-of-the-art equipment.


Address:

8 Xinrui Road, Xin Wu District, Wuxi, Jiangsu, 214028, China

Middletown_DE.png

Middletown, DE, USA

Peptide formulation development and manufacturing

In June 2021, WuXi STA announced that it will build a new pharmaceutical manufacturing campus in Middletown, Delaware US.  The 190-acre new facility in Middletown will feature space for testing laboratories; formulation R&D; and manufacture and packaging of oral solid pharmaceutical products and sterile products, which is expected to start operation in 2025. 

Middletown DE USA

Peptide manufacturing_Chengdu

Chengdu, China

Unnatural amino acid synthesis

Chengdu site has an experienced team to provide all types of custom chemistry synthesis, plus one dedicated team to provide custom synthesis for unnatural amino acids and other peptide related building blocks. The team has built a comprehensive library with 2,500+ unnatural amino acids as catalog products.

Address:

No.388 Haifa Road, Chengdu Cross-Strait Science & Technology Industrial Development Park, Wenjiang District

Chengdu, 611138, China